Somnomed Ltd
ASX:SOM
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Somnomed Ltd
ASX:SOM
|
131.8m AUD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
197.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
176.1B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
146.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.3B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.3B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.8B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.6B USD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Somnomed Ltd
Glance View
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Somnomed Ltd is 59.9%, which is below its 3-year median of 60.8%.
Over the last 3 years, Somnomed Ltd’s Gross Margin has decreased from 61% to 59.9%. During this period, it reached a low of 59.9% on Jun 30, 2025 and a high of 62.1% on Jun 30, 2023.
